Abstract
EBV viral load (EBV-VL) in PBMC was prospectively determined by semi-quantitative PCR in 85 stem cell transplants (40 genoidentical, 45 non-genoidentical) in order to characterize the kinetics of EBV-VL and to assess the ability of this measure to predict the development of EBV-induced lymphoproliferative disease (EBV-LPD). PCR was performed prior to and after transplantation. An EBV-VL >300 copies/μg DNA was chosen as the threshold for risk of developing an EBV-LPD. Two hundred and fifty-eight EBV-VL measures were evaluable. Five patients (5.9%) developed an EBV-LPD. All had an elevated EBV DNA peak level before EBV-LPD. Fifteen out of 80 recipients (18.7%) without EBV-LPD had EBV levels over 300 copies/μg DNA at least once during the follow-up. Overall, the manifestation of at least one EBV-VL over 300 copies/μg DNA during the entire follow-up demonstrated a sensitivity, specificity, positive and negative predictive value for the diagnosis of EBV-LPD of 100%, 81%, 25% and 100%, respectively. In patients without EBV-LPD, HLA incompatibility, grade ⩾II acute GVHD and use of an unmanipulated graft were significantly associated with an EBV-VL >300 copies/μg DNA. This strategy appears sensitive for the diagnosis of EBV-LPD but its positive predictive value has to be improved in order to guide pre-emptive therapy.
Bone Marrow Transplantation (2002) 29, 21–28. doi:10.1038/sj.bmt.1703331
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL . Epstein–Barr virus, immunodeficiency, and B cell lymphoproliferation Transplantation 1985 39: 461 472
Shapiro RS, McClain K, Frizzera G et al. Epstein–Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation Blood 1988 71: 1234 1243
Zutter MM, Martin PJ, Sale GE et al. Epstein–Barr virus lymphoproliferation after bone marrow transplantation Blood 1988 72: 520 529
Micallef INM, Chhanabhai M, Gascoyne RD et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience Bone Marrow Transplant 1998 22: 981 987
Swerdlow SH . Post-transplant lymphoproliferative disorders: a morphologic, phenotypic and genotypic spectrum of disease Histopathology 1992 20: 373 385
Gross TG, Steinbuch M, DeFor T et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome Bone Marrow Transplant 1999 23: 251 258
Antin JH, Bierer BE, Smith BR et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies Blood 1991 78: 2139 2149
Gerritsen EJA, Stam ED, Hermans J et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children Bone Marrow Transplant 1996 18: 377 382
Hale G, Waldmann H . Risks of developing EBV-LPD after T cell-depleted marrow transplantation Blood 1998 91: 3079 3083
Martin PJ, Shulman HM, Scubach WH et al. Fatal Epstein–Barr virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody Ann Intern Med 1984 101: 310 315
Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study Blood 1999 94: 2208 2216
Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation New Engl J Med 1994 324: 1451 1456
Rooney CM, Smith CA, Ng CYC et al. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr virus-related lymphoproliferation Lancet 1995 345: 9 13
Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes Nat Med 1996 2: 551 555
O‘Reilly RJ, Lacerda JF, Lucas KG et al. Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants. In : DeVita V, Hellman S, Rosenberg SA (eds) Important Advances in Oncology Lippincott: Philadelphia 1996 pp 149 166
Heslop HE, Rooney CM . Adoptive cellular immunotherapy for EBV lymphoproliferative diseases Immunol Rev 1997 157: 217 222
O'Reilly RJ, Small TN, Papadopoulos E et al. Biology and adoptive cell therapy of Epstein–Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts Immunol Rev 1997 157: 195 216
Rooney CM, Smith CA, Ng CYC et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients Blood 1998 92: 1549 1555
Gustafsson A, Levitsky V, Zou JZ et al. Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells Blood 2000 95: 807 814
Faye A, Van Den Abeele T, Peuchmaur M et al. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders Lancet 1998 352: 1285
Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients Ann Oncol 2000 11 (Suppl. 1): S113 S116
Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hematopoietic stem-cell transplantation Blood 2000 95: 1502 1505
Riddler SA, Breinig MC, McKnight JK . Increased levels of circulating Epstein–Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of post-transplant lymphoproliferative disease in solid-organ transplant recipients Blood 1994 84: 972 984
Savoie A, Perpete C, Carpentier L et al. Direct correlation between the load of Epstein–Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease Blood 1994 83: 2715 2722
Kenagy DN, Schlesinger Y, Weck K et al. Epstein–Barr virus DNA in peripheral blood leukocytes of patients with post-transplant lymphoproliferative disease Transplantation 1995 60: 547 554
Rooney CM, Loftin SK, Holladay MS et al. Early identification of Epstein–Barr virus-associated post-transplantation lymphoproliferative disease Br J Haematol 1995 89: 98 103
Lucas KG, Burton RL, Zimmerman SE et al. Semiquantitative Epstein–Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation Blood 1998 91: 3654 3661
Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 1974 18: 295 304
Herve P, Bordigoni P, Cahn JY et al. Use of monoclonal antibodies in vivo as therapeutic strategy for acute GVHD in matched and mismatched bone marrow transplantation Transplant Proc 1991 23: 1692 1694
Buisson M, Morand P, Peoc'h M et al. Development of an Epstein–Barr virus type 2 (EBV-2)-associated hepatic B cell non-Hodgkin's lymphoma in an HIV-1-infected patient following a change in the EBV dominant type Leukemia 1999 13: 298 301
Haddad E, Paczesny S, Leblond V et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: multicenter phase 1–2 clinical trial Blood 2001 97: 1590 1597
Fina F, Romain S, Ouafik L et al. Frequency and genome load of Epstein–Barr virus in 509 breast cancers from different geographical areas Br J Cancer 2001 84: 783 790
Miyashita EM, Yang B, Lam KM et al. A novel form of Epstein–Barr virus latency in normal B cells in vivo Cell 1995 80: 593 601
Sirvent N, Reviron D, de Lamballerie X, Michel G . First report of Epstein–Barr virus lymphoproliferative disease after cord blood transplantation Bone Marrow Transplant 2000 25: 120 121
Faye A, Quartier P, Reguerre Y et al. Chimeric anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorders (B-PTLD) following stem cell transplantation in children Br J Haematol 2001 115: 112 118
Allen U, Hebert D, Petric M et al. Utility of semiquantitative polymerase chain reaction for Epstein–Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease Clin Infect Dis 2001 33: 145 150
Beck R, Westdörp I, Jahn G et al. Detection of Epstein–Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow or peripheral stem cell transplantation J Clin Microbiol 1999 37: 3430 3431
Kimura H, Morita M, Yabuta Y et al. Quantitative analysis of Epstein–Barr virus load by using a real-time PCR assay J Clin Microbiol 1999 37: 132 136
Baldanti F, Grossi P, Furione M et al. High levels of Epstein–Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders J Clin Microbiol 2000 38: 613 619
Niesters HGM, van Esser J, Fries E et al. Development of a real-time quantitative assay for detection of Epstein–Barr virus J Clin Microbiol 2000 38: 712 715
Brengel Pesce K, Morand P, Schmuck A et al. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein–Barr virus infections J Med Virol (in press)
Stevens SJ, Verschuuren EA, Pronke I et al. Frequent monotoring of Epstein–Barr virus DNA in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients Blood 2001 97: 1165 1171
Fontan J, Bassignot A, Mougin C et al. Detection of Epstein–Barr virus DNA in serum of transplanted patients: a new diagnostic guide for lymphoproliferative diseases Leukemia 1998 12: 772 775
Limaye AP, Huang ML, Atienza EE et al. Detection of Epstein–Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders J Clin Microbiol 1999 37: 1113 1116
Rose C, Green M, Webber S et al. Pediatric solid-organ transplant recipients carry chronic loads of Epstein–Barr virus exclusively in the immunoglobulin D-negative B-cell compartment J Clin Microbiol 2001 39: 1407 1415
Rickinson AB, Moss DJ . Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection Annu Rev Immunol 1997 15: 405 431
Flinn I, Orentas R, Noga SJ et al. Low risk of Epstein–Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) in patients receiving elutriated allogeneic marrow transplants may reflect depletion of EBV infected lymphocytes from the graft Blood 1995 86 (Suppl. 1): 626a (Abstr. 2490)
Hale G, Waldmann H for CAMPATH users. Risk of developing Epstein–Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants Blood 1998 91: 3079 3083
Cavazzana-Calvo M, Bensoussan D, Jabado N et al. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation Br J Haematol 1998 103: 543 551
Bonnefy-Berard N, Flacher M, Revillard JP . Antiproliferative effect of antilymphocyte globulins on B cells and B-cell lines Blood 1992 79: 2164 2170
Lucas KG, Smail TN, Heller G et al. The development of cellular immunity to Epstein–Barr virus following allogeneic bone marrow transplantation Blood 1996 87: 2594 2603
Frank D, Cesarman E, Liu YF et al. Post-transplantation lymphoproliferative disorders frequently contain type A and not type B Epstein–Barr virus Blood 1995 85: 1396 1403
Acknowledgements
This work was supported by grant from the Association pour la Recherche contre le Cancer (ARC), Villejuif, France
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sirvent-von Bueltzingsloewen, A., Morand, P., Buisson, M. et al. A prospective study of Epstein–Barr virus load in 85 hematopoietic stem cell transplants. Bone Marrow Transplant 29, 21–28 (2002). https://doi.org/10.1038/sj.bmt.1703331
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703331
Keywords
This article is cited by
-
EBV post transplantation lymphoproliferative disease-associated pneumomediastinum in a pediatric patient with long-lasting low loads of plasma EBV-DNA positivity
Bone Marrow Transplantation (2008)
-
Preemptive diagnosis and treatment of Epstein–Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development
Bone Marrow Transplantation (2006)